ClinicalTrials.gg
RecruitingNCT07361003Updated Jan 22, 2026

A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer

A Phase 3 interventional study of Suvemcitug injection, trifluridine/tipiracil tablets and Suvemcitug placebo injection, trifluridine/tipiracil tablets in Refractory Metastatic Colorectal Cancer, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
464
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,136 studies in Colorectal Neoplasms with a site in China — 526 open to participants now, 604 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
98th of 891
464 · median 80
Started
2025
with 124 others
Phase 3
124 of 1,136
45 open now
Primary completion
2028-01
later than 477 of 603 live
Registered
968th of 1,136
by date

Among the 1,136 studies in Colorectal Neoplasms with a site in China, this one is the 98th largest by planned enrollment of the 891 interventional ones that give a count, is one of 125 that started in 2025, is one of 124 in phase 3, reaches primary completion later than 477 of the 603 other live ones, and was the 968th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

526 of the 1,136 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

521 more — sign in →

All 526 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,136 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants.

The primary goal of Phase III Study is to evaluate the efficacy of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. Researchers will compare Suvemcitug + trifluridine/tipiracil tablets with placebo (a look-alike substance that contains no drug)+ trifluridine/tipiracil tablets to see if Suvemcitug + trifluridine/tipiracil tablets works better in treating refractory metastatic colorectal cancer.

Read the detailed description

The study will enroll approximately 464 participants (30 for Phase Ib and 434 for Phase III stage) with refractory metastatic colorectal cancer who have previously received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy, and who have either previously received or are unsuitable for anti-vascular endothelial growth factor (VEGF) therapy or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild-type).

For Phase Ib Study, all 30 participants will be receiving the treatment with Suvemcitug in combination with trifluridine/tipiracil tablets. For Phase III Study, approximately 434 participants will be randomly assigned in a 1:1 ratio to two groups. One group will receive treatment with Suvemcitug + trifluridine/tipiracil tablets. The other group will receive the treatment with placebo + trifluridine/tipiracil tablets.

All participants will receive study treatment until they meet the criteria for treatment discontinuation. During study treatment period, investigators will evaluate the efficacy, safety and participants' quality of life. After treatment discontinuation, investigators will continue to follow up for subsequent treatment and survival information until the criteria for study discontinuation are met.

By the end of study, for participants who are still receiving study treatment, if their efficacy evaluation result is stable or response and they are tolerant to the treatment, then after obtaining approval from health regulatory authorities and ethics committees, they can continue study treatment by joining another extension study or in other ways as discussed by the sponsor.

03

Conditions studied

  • Refractory Metastatic Colorectal Cancer

Keywords

  • refractory metastatic colorectal cancer
  • Suvemcitug
  • trifluridine/tipiracil
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Confirmed by histological and/or cytological examination as unresectable colon or rectal adenocarcinoma;
  • 2. At least one measurable tumor lesion ( v1.1);
  • 3. Previously received fluorouracil, oxaliplatin, and irinotecan based chemotherapy; had previously undergone or was unsuitable for anti-VEGF therapy. (For participants with RAS wild-type, had previously undergone or was unsuitable for anti-EGFR therapy.);
  • 4. metastatic colorectal cancer having progressed on or are intolerant to the last systemic treatment;
  • 5. Good organ and bone marrow function (no administration of hematopoietic growth factors, blood transfusion, or within 14 days before screening hematology test);
  • 6. RAS mutation status confirmed by testing tumor tissue and /or blood sample.

Exclusion criteria

Exclusion Criteria:

  • 1. Having a second active primary within the past 5 years;
  • 2. Symptomatic central nervous system (CNS) or requiring local CNS-directed therapy (e.g., radiotherapy or surgery) or treatment within 2 weeks prior to the first administration of the study treatment;
  • 3. Any active infection requiring systemic treatment within 2 weeks prior to the initiation of the study treatment;
  • 4. Pleural effusion, pericardial effusion, or ascites that is uncontrolled or has required drainage or medical intervention within 4 weeks prior to the first administration of the study treatment;
  • 5. Received systemic immuno suppressive therapy within 4 weeks prior to randomization (excluding prophylactic use or chronic low-dose steroids [≤20 mg/day prednisone equivalent dose]);
  • 6. Currently taking or has recently taken (within 10 days prior to the first dose) aspirin (>325 mg/day);
  • 7. Active or chronic (HBsAg or HBcAb positive and HBV DNA≥2000 IU/mL or ≥10000 copies/mL) or infection (HCV antibody positive and HCV RNA≥);
  • 8. cardiovascular disease within 6 months prior to the first administration of the study treatment;symptomatic coronary artery disease requiring medication; arrhythmia requiring medication (excluding asymptomatic atrial fibrillation with controlled ventricular rate); interval >470 ms at rest state; or uncontrolled hypertension or pulmonary hypertension;
  • 9. Known hereditary or acquired bleeding and thrombotic tendencies (e.g., hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.); clinically significant bleeding events, arterial or deep venous thrombotic events, or superficial venous thrombosis and intermuscular venous thrombosis requiring intervention within 6 months prior to enrollment;
  • 10. Participants with proteinuria (urine protein >2+ found during screening examinations; or urine protein 2+ with 24-hour urine protein quantification ≥1g/24h);
  • 11. Participants with a history of intestinal obstruction (including incomplete intestinal obstruction) within 1 month prior to enrollment; participants with a history of abdominal fistula, gastrointestinal perforation, or abdominal abscess.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
464 participants (estimated)

Study arms

  • Experimental
    Suvemcitug+ trifluridine/tipiracil tablets

    Participants will receive Suvemcitug injection (at 1.5mg/kg for Phase Ib; and a recommended dose level based on Phase Ib result will be used for Phase III part) on Day 1 and Day 15 of each cycle (28 days), and trifluridine/tipiracil tablets at 35 mg/m² on day 1-5, 8-12 of each cycle (28 days), until disease progression, intolerable adverse event, participant withdrawal, or meet other discontinuation criteria as described by the protocol.

    Drug: Suvemcitug injection, trifluridine/tipiracil tablets

  • Placebo comparator
    Placebo+ trifluridine/tipiracil tablets

    Participants will receive Suvemcitug placebo injection on Day 1 and Day 15 of each cycle (28 days), and trifluridine/tipiracil tablets at 35 mg/m² on day 1-5, 8-12 of each cycle (28 days), until disease progression, intolerable adverse event, participant withdrawal, or meet other discontinuation criteria as described by the protocol.

    Drug: Suvemcitug placebo injection, trifluridine/tipiracil tablets

Interventions

  • DrugSuvemcitug injection, trifluridine/tipiracil tablets

    Drug pages: Suvemcitug · Trifluridine · Tipiracil

    Suvemcitug injection at 1.5mg/kg, Trifluridine/tipiracil tablets at 35 mg/m²

  • DrugSuvemcitug placebo injection, trifluridine/tipiracil tablets

    Suvemcitug placebo injection, Trifluridine/tipiracil tablets at 35 mg/m².

06

What researchers measure

Primary outcomes

  1. Phase Ib: dose limiting toxicity (DLT)

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Phase Ib: Adverse Events

    The incidence (number of participants) and severity of adverse events (AE) and serious adverse events (SAE) assessed by CTCAE v5.0

    Time frame: From signing informed consent form until 28 days after the last dose of study treatment, up to about 18 months

  3. Phase Ib: Tolerance

    Number of participants who experienced adverse event related dose interruption, dose reduction and treatment discontinuation as assessed by investigators.

    Time frame: From signing informed consent until 28 days after the last dose of study treatment, for up to 18 months

  4. Phase III: overall survival (OS)

    OS is the time interval from the date of randomization to death from any cause.

    Time frame: For about 18 months from the randomization of the last participant

Secondary outcomes

  1. Suvemcitug Serum concentration change over time of all participants

    Area under the serum concentration versus time curve (AUC)

    Time frame: For about 6 cycles, each cycle is 28 days.

  2. Peak Suvemcitug serum concentration (Cmax) of all participants

    Time frame: For about 6 cycles, each cycle is 28 days

  3. The time taken to reach peak Suvemcitug concentration after administration (Tmax)

    Time frame: For about 6 cycles, each cycle is 28 days

  4. The time required for Suvemcitug concentration in the serum to decrease by half (t1/2)

    Time frame: For about 6 cycles, each cycle is 28 days

  5. Serum anti-drug antibody (ADA) incidence of Suvemcitug

    The number of participants with anti-drug antibody (ADA) tested positive from blood

    Time frame: For about 6 cycles, each cycle is 28 days

  6. Serum anti-drug antibody (ADA) duration of Suvemcitug

    Duration of ADA measures how long the antibody persists in the blood

    Time frame: For about 6 cycles, each cycle is 28 days

  7. Serum anti-drug antibody (ADA) titer of Suvemcitug

    ADA titer measures how much anti-drug antibody is present in the blood

    Time frame: For about 6 cycles, each cycle is 28 days

  8. Objective Response Rate (ORR) of all participants

    Proportion of participants who have a complete or partial response relative to baseline as assessed according to RECIST 1.1 criteria

    Time frame: From the date when the first dose of Suvemcitug is administered until radiological progression, initiation of new anti-cancer therapy, death or withdrawal from study, whichever came first, assessed up to 18 months.

  9. Duration of response (DoR) of all participants

    Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.

    Time frame: From the date when the first dose of Suvemcitug is administered until radiological progression, initiation of new anti-cancer therapy, death or withdrawal from study, whichever came first, assessed up to 18 months

  10. Disease control rate (DCR) of all participants

    Proportion of participants who have a complete or partial response, or stable disease relative to baseline as assessed according to RECIST 1.1 criteria

    Time frame: From the date when the first dose of Suvemcitug is administered until radiological progression, initiation of new anti-cancer therapy, death or withdrawal from study, whichever came first, assessed up to 18 months.

  11. Progression free survival (PFS) of all participants

    Time frame: From the date when the first dose of Suvemcitug is administered until radiological progression, initiation of new anti-cancer therapy, death or withdrawal from study, whichever came first, assessed up to 18 months.

  12. Phase Ib: overall survival (OS)

    OS is the time interval from the date of randomization to death from any cause

    Time frame: For about 18 months from the randomization of the last participant

  13. Phase III: Adverse Events

    The incidence (number of participants) and severity of adverse events (AE) and serious adverse events (SAE) assessed by CTCAE v5.0

    Time frame: From signing informed consent form until 28 days after the last dose of study treatment, for about 18 months.

  14. Phase III: quality of life - EORTC QLQ-C30

    Quality of life evaluated by participant reported questionnaires: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 .

    Time frame: Questionnaires will be collected from participants at baseline, and all efficacy evaluation visits, for up to 18 months

  15. Phase III: quality of life - Euro Qol (EQ)-5D

    Evaluated by participant reported questionnaires: EuroQol- 5 Dimension Questionnaire.

    Time frame: Questionnaires will be collected from participants at baseline, and all efficacy evaluation visits, for up to 18 months

07

Study locations

6 of 6 sites recruiting
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Recruiting
  • Harbin Medical University University Cancer Hospital
    Harbin, Heilongjiang, China
    Recruiting
    • Yanqiao Zhang · Contactyanqiaozhang@126.com · +86-451-86298000
    • Yanqiao Zhang · Principal investigator
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210029, China
    Recruiting
    • Yanhong Gu · Contactguluer@163.com · +86-25-83714511
    • Yanhong Gu · Principal investigator
  • Cancer Hospital of Shandong First Medical University
    Jinan, Shandong, China
    Recruiting
    • Shuqin Ni · Contactnsq163@163.com · 0086-0531-87984777
    • Shuqin Ni · Principal investigator
    • Zuoxing Niu · Principal investigator
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
    Recruiting
    • Kefeng Ding · Contactdingkefeng@zju.edu.cn · +86-571-87783777
    • Kefeng Ding · Principal investigator
    • Ying Yuan · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jan 2028, 26 months after the start.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's planned 26 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Jan 22, 2026
StartActual
Nov 12, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jul 2028
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07361003
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Nov 12, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jan 22, 2026

Study contacts

Xueyan Li
Contact
lixueyan1@zaiming.com
+86-25-85566666

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Suvemcitug · Trifluridine · Tipiracil

Start the discussion